By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its second-quarter revenues increased 35 percent as sales of its clinical systems climbed 53 percent year over year.

The Sunnyvale, Calif.-based molecular diagnostics firm brought in total revenues of $67 million for the three-month period ended June 30, compared to $49.6 million for the second quarter of 2010. It easily beat analysts' consensus estimate for revenues of $61 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.